D.E. Shaw & Co
NTLA icon

D.E. Shaw & Co’s Intellia Therapeutics NTLA Stock Holding History

D.E. Shaw & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
6,443,323
+715,146
+12% +$10M 0.05% 418
2026
Q1 		$73.4M Buy
5,728,177
+397,113
+7% +$5.06M 0.04% 500
2025
Q4 		$47.9M Buy
5,331,064
+3,102,664
+139% +$42.7M 0.03% 727
2025
Q3 		$38.5M Buy
2,228,400
+1,403,673
+170% +$17.3M 0.02% 791
2025
Q2 		$7.74M Buy
824,727
+792,331
+2,446% +$6.51M 0.01% 1696
2025
Q1 		$230K Sell
32,396
-1,187
-4% -$12K ﹤0.01% 3877
2024
Q4 		$392K Buy
33,583
+21,303
+173% +$332K ﹤0.01% 3759
2024
Q3 		$252K Buy
+12,280
New +$283K ﹤0.01% 4062
2023
Q1 		– Sell
-15,152
Closed -$529K – 4727
2022
Q4 		$529K Sell
15,152
-36,419
-71% -$1.73M ﹤0.01% 3825
2022
Q3 		$2.89M Sell
51,571
-374,779
-88% -$23.2M ﹤0.01% 2676
2022
Q2 		$22.1M Buy
426,350
+207,941
+95% +$10.6M 0.03% 802
2022
Q1 		$15.9M Buy
218,409
+215,775
+8,192% +$18.3M 0.01% 1198
2021
Q4 		$311K Sell
2,634
-7,398
-74% -$927K ﹤0.01% 4662
2021
Q3 		$1.35M Sell
10,032
-104,960
-91% -$15.9M ﹤0.01% 3371
2021
Q2 		$18.6M Sell
114,992
-288,728
-72% -$22.5M 0.02% 1064
2021
Q1 		$32.4M Buy
403,720
+42,349
+12% +$2.84M 0.03% 681
2020
Q4 		$19.7M Buy
361,371
+189,402
+110% +$6.88M 0.02% 964
2020
Q3 		$3.42M Sell
171,969
-22,492
-12% -$469K ﹤0.01% 1973
2020
Q2 		$4.09M Buy
+194,461
New +$3.3M ﹤0.01% 1805
2020
Q1 		– Sell
-12,625
Closed -$185K – 4146
2019
Q4 		$185K Buy
+12,625
New +$176K ﹤0.01% 3819

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's NTLA Position: Q2 2026 in Review

D.E. Shaw & Co increased its Intellia Therapeutics (NTLA) stake by 12% in Q2 2026, buying an estimated $10M and bringing the position to 6,443,323 shares worth $109M. The position accounts for 0.05% of the portfolio, ranked #418.

D.E. Shaw & Co first reported a position in NTLA in Q4 2019 and has held it in 20 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • D.E. Shaw & Co held 6,443,323 shares of Intellia Therapeutics worth $109M as of Q2 2026.
  • D.E. Shaw & Co bought 715,146 Intellia Therapeutics shares in Q2 2026, an estimated $10M.
  • Intellia Therapeutics made up 0.05% of D.E. Shaw & Co's portfolio in Q2 2026, its #418 holding.
  • D.E. Shaw & Co first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.